Literature DB >> 6487502

Xipamide: no advantage over bendrofluazide in hypertension.

L E Ramsay, S Freestone.   

Abstract

In patients with uncontrolled hypertension addition of xipamide 20 mg daily to bendrofluazide 5 mg daily produced no significant additive antihypertensive effect, and the 95% confidence limits excluded a clinically important response. Xipamide treatment worsened hypokalaemia and increased the blood urea concentration significantly.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6487502      PMCID： PMC1463626          DOI： 10.1111/j.1365-2125.1984.tb02514.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  7 in total

1.  Xipamide and cyclopenthiazide in essential hypertension--comparative effects on blood pressure and plasma potassium.

Authors:  G A MacGregor; R A Banks; N D Markandu; J Roulston
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

2.  [Pharmacological and toxicological properties of the saluretic xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide)].

Authors:  F Leuschner; W Neumann; H Bahrmann
Journal:  Arzneimittelforschung       Date:  1975-02

3.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

4.  A study of the antihypertensive action of xipamide using ambulatory intra-arterial monitoring.

Authors:  E B Raftery; D I Melville; B A Gould; S Mann; J R Whittington
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

5.  Sample size for short-term trials of antihypertensive drugs.

Authors:  S Freestone; J H Silas; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial.

Authors:  D Bonaduce; N Ferrara; M Petretta; V Canonico; E Romango; F Rengo
Journal:  Curr Med Res Opin       Date:  1981       Impact factor: 2.580

7.  Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.

Authors:  A J Marshall; D W Barritt; J Pocock; S T Heaton
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321
  7 in total
  1 in total

Review 1.  Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B N Prichard; R N Brogden
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.